Noble Financial Thinks Agile Therapeutics’ Stock is Going to Recover

By Ryan Adsit

Noble Financial analyst Mark Jordan reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) on March 9. The company’s shares closed last Friday at $2.40, close to its 52-week low of $1.82.

According to, Jordan is a 3-star analyst with an average return of 2.9% and a 50.0% success rate. Jordan covers the Services sector, focusing on stocks such as Information Services Group, Salem Communications Corp, and Entercom Communications.

Agile Therapeutics has an analyst consensus of Strong Buy.

The company has a one year high of $8.65 and a one year low of $1.82. Currently, Agile Therapeutics has an average volume of 593.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The company focuses on the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company products include Twirla AG200, AG200-ER and AG200-SP. Agile Therapeutics was founded on December 22, 1997 and is headquartered in Princeton, NJ.